Publications Using MCE Products

Hou, J., Qu, F., Wu, C., Ren, Q. & Zhang, J. Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography–tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis 66, 232-239 (2012). Liu, Q. et al. Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. Cancer research 73, 2574-2586 (2013). Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J. & Hodi, F. S. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clinical Cancer Research 19, 598-609 (2013). Matsumoto, H. et al. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. Cancer research 73, 5206-5217 (2013). Portelius, E. et al. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. Journal of Alzheimer's Disease 21, 1005-1012 (2010). Lis, P. et al. Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. Journal of bioenergetics and biomembranes 44, 155-161 (2012). Shin, H. J., Shon, D. H. & Youn, H. S. Isobavachalcone suppresses expression of inducible nitric oxide synthase induced by Toll-like receptor agonists. International immunopharmacology 15, 38-41 (2013). Lu, J. et al. In vitro and in vivo Activities of a New Lead Compound I2906 against Mycobacterium tuberculosis. Pharmacology 85, 365-371 (2010). Shrestha, R. L. & Draviam, V. M. Lateral to End-on Conversion of Chromosome-Microtubule Attachment Requires Kinesins CENP-E and MCAK. Current Biology 23, 1514-1526 (2013). Yuan, J. et al. The effects of jatrorrhizine on contractile responses of rat ileum. European journal of pharmacology 663, 74-79 (2011). Liu, Q. et al. Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. Cancer research 73, 2574-2586 (2013). Elkabets, M. et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Science translational medicine 5, 196ra199-196ra199 (2013). Weisberg, E. et al. Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells. PloS one 8, e56473 (2013). Chan, C. T. et al. Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated mice. Hypertension 60, 1207-1212 (2012). Sun, J. & Murphy, E. Calcium-sensing receptor: a sensor and mediator of ischemic preconditioning in the heart. American Journal of Physiology-Heart and Circulatory Physiology 299, H1309-H1317 (2010). Miederer, I. et al. Evaluation of cannabinoid type 1 receptor expression in the rat brain using [(1)(8)F]MK-9470 microPET. European journal of nuclear medicine and molecular imaging 40, 1739-1747 (2013). Lancia JK, et al. Sequence context and crosslinking mechanism affect the efficiency of in vivo capture of a protein-proteininteraction. Biopolymers. 2013 Aug 27 Flasse LC, et al. Ascl1b and Neurod1, instead of Neurog3, control pancreatic endocrine cell fate in zebrafish. BMC Biol. 2013 Jul 8; 11:78. Logarinho E, et al. CLASPs prevent irreversible multipolarity by ensuring spindle-pole resistance to traction forces duringchromosome alignment. Nat Cell Biol. 2012 Feb 5;14(3):295-303. Kim HY, et al. Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis Cvirus antivirals. Antiviral Res. 2013 Jul;99(1):6-11. Barot M, et al. Monocarboxylate transporter mediated uptake of moxifloxacin on human retinal pigmented epithelium cells. J Pharm Pharmacol. 2013 Sep 1

Customer Reviews

  • New Products
  • 267 New Products Within 30 Days

  • See More >
  • Poliumoside
  • "
  • PathWay: Others

    Target: Others

    Poliumoside is a nutural compound which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM.

  • MORE
  • Isoacteoside
  • "
  • PathWay: Others

    Target: Others

    Isoacteoside is a natural compound which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM, compared with those of aminoguanidine (IC50=1,056 μM) and quercetin (IC50=28.4 μM) as positive controls.

  • MORE
  • Verbascoside
  • "
  • PathWay: Others

    Target: Others

    Verbascoside(Acteoside; TJC160), is a bioactive polyphenol from olive oil mill wastewater with known antioxidant activity; protein kinase C inhibitor (IC50 =25 uM).

  • MORE